Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCheckit Regulatory News (CKT)

Share Price Information for Checkit (CKT)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
24.00
Ask:
26.00
Spread: 2.00 (8.333%)
Market Cap: £27.00m
CKT Live PriceLast checked at - London Stock Exchange

Intraday Checkit Share Chart

Trading Statement

2 Nov 2017 07:00

RNS Number : 3058V
Elektron Technology PLC
02 November 2017
 

Elektron Technology plc

("Elektron", the "Group" or the "Company")

 

Trading Update

 

Elektron Technology plc (AIM: EKT), the global technology group, is pleased to provide an update on trading for the third quarter ended 31 October 2017.

Sales

Group trading was strong in Q3 with sales increasing 34% compared to the same period last year to £8.6m (2017: £6.4m). Year to date sales have increased by 15% to £22.9m (2017: £19.9m).

Bulgin achieved record quarterly sales of £7.8m in Q3, 37% higher than the same period last year (2017: £5.7m) following successful manufacturing scale-up to convert the unprecedented order demand in H1 into sales. The board expects that Bulgin sales will revert to more normal levels through Q4.

 

Sales £m

Unaudited

Unaudited

Q3 2018

Q3 2017

YTD 2018

YTD 2017

Bulgin

7.8

5.7

20.3

17.4

IMC (Queensgate and Elektron Eye Technology)

0.7

0.7

2.3

2.3

Checkit

0.1

0.3

0.2

 

Total

 

8.6

 

6.4

 

22.9

 

19.9

 

Orders

Group order intake remains well ahead of prior year, with all business segments demonstrating growth.

Bulgin and IMC orders are both 20% above prior year levels year to date.

Checkit has continued to build recurring revenue streams and total contracted annual recurring revenue (including forthcoming contracted installations) now stands at £0.7m, compared with £0.3m at the same time last year (+133%).

Cash

Group net cash was approximately £3.0m at 31 October 2017 (31 July 2017: £2.0m; 31 January 2017: £1.0m) following the initial proceeds from the Sheen Instruments disposal of £1.1m in October. The net cash position has also been impacted by investment in working capital of approximately £0.4m as a result of the strong trading performance in this quarter.

John Wilson, Chief Executive Officer of Elektron, said:

"Q3 trading has been strong. The Board now expects full year performance to be ahead of its previous expectations."

Enquiries:

 

Elektron Technology plc 

www.elektron-technology.com

 

+44 (0) 1223 371 000

John Wilson - Chief Executive Officer

 

Andy Weatherstone - Chief Financial Officer & Company Secretary

 

 

 

finnCap (Nominated Adviser & Broker)

+44 (0)20 7220 0500

Ed Frisby / Scott Mathieson - Corporate Finance

 

Abigail Wayne - Corporate Broking

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

Notes to Editors

Elektron conceives designs and markets innovative engineered products and services for businesses that connect, monitor and control. We have a multi skilled team of engineers, software and product line specialists based in Cambridge focused on the opportunities created by global trends in the following areas:

 

- Demand for ubiquitous power and data: Bulgin

- New waves of "aware" business applications: Checkit

- The effect of ageing on sight: Elektron Eye Technology

- Growth in high precision manufacture: Queensgate

 

Cautionary statement

This financial information has been prepared only for the shareholders of Elektron as a whole and its sole purpose and use is to assist shareholders to exercise their governance rights. Elektron and its Directors and employees are not responsible for any other purpose or use or to any other person in relation to this report.

The report contains indications of likely future developments and other forward-looking statements that are subject to risk factors associated with, among other things, the economic and business circumstances occurring from time to time in the countries, sectors and business segments in which the Group operates. Key risks and their mitigation have not changed materially in the period from those disclosed on pages 12 to 14 of the annual financial statements for the year ended 31 January 2017.

These and other factors could adversely affect the Group's results, strategy and prospects. Forward-looking statements involve risks, uncertainties and assumptions. They relate to events and/or depend on circumstances in the future which could cause actual results and outcomes to differ materially from those currently anticipated. No obligation is assumed to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBUBDBCSGBGRB
Date   Source Headline
7th Jun 20217:00 amRNSAppointment of Non-Executive Director
3rd Jun 202112:25 pmRNSResult of AGM
13th May 20217:00 amRNSTrading Update
10th May 202112:23 pmRNSPosting of Annual Report and Notice of AGM
4th May 20214:02 pmRNSDirector Dealing
29th Apr 202110:00 amRNSBoard Changes
29th Apr 20217:00 amRNSPreliminary Results
21st Apr 20217:00 amRNSProduct update announcement
23rd Mar 20213:54 pmRNSHolding(s) in Company
22nd Mar 202112:33 pmRNSHolding(s) in Company
19th Mar 20217:00 amRNSElectronic Communications
22nd Feb 20217:00 amRNSDirector/PDMR Shareholding
18th Feb 20217:00 amRNSGrant of options and PDMR dealings
11th Feb 20217:00 amRNSTrading Update
4th Feb 20217:00 amRNSAcquisition and Business Development Appointments
21st Dec 20205:14 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSDirector Dealing, Exercise of Options and TVR
2nd Dec 20207:00 amEQSCheckit (CKT): Initiation - Smarter operations management
2nd Dec 20207:00 amRNSEdison Investment Research Initiates Coverage
1st Dec 20202:30 pmEQSCheckit (CKT): Initiation - Smarter operations management
10th Nov 20207:00 amRNSTrading Update
19th Oct 20207:00 amRNSContract with John Lewis
24th Sep 20207:00 amRNSBoard Changes
21st Sep 20204:27 pmRNSPDMR Dealing
16th Sep 20207:00 amRNSHalf Year Results
12th Aug 20207:00 amRNSTrading update and notice of interim results
6th Aug 20207:00 amRNSBoard Changes
31st Jul 20201:54 pmRNSResult of AGM
9th Jul 20203:38 pmRNSPDMR Dealing
7th Jul 202010:34 amRNSGrant of share options and PDMR dealings
7th Jul 20207:38 amRNSPosting of Annual Report and Notice of AGM
6th Jul 20207:00 amRNSAppointment of CFO designate
1st Jul 202012:40 pmRNSDisposal of assets
16th Jun 20207:00 amRNSPreliminary Results
2nd Jun 20204:15 pmRNSChange to AGM date and arrangements
26th May 20207:00 amRNSCOVID-19 Update and Change to Results Date
5th May 20205:03 pmRNSResignation of Director
21st Apr 20203:20 pmRNSDirector/PDMR Shareholding
14th Apr 20207:00 amRNSCOVID-19 Update
23rd Mar 20206:11 pmRNSDirector/PDMR Shareholding
18th Mar 20205:15 pmRNSDirector/PDMR Shareholding
21st Feb 20204:41 pmRNSSecond Price Monitoring Extn
21st Feb 20204:35 pmRNSPrice Monitoring Extension
21st Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSPDMR Dealing and Concert Party Holdings
13th Feb 20207:00 amRNSTrading Update
3rd Feb 20207:00 amRNSAppointment of Non-Executive Director
23rd Dec 20195:05 pmRNSHolding(s) in Company
18th Dec 20196:25 pmRNSPDMR Dealings
16th Dec 201911:40 amRNSResignation of Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.